



To: UPHS Physicians and Staff  
From: Department of Pathology and Laboratory Medicine  
Division of Precision and Computational Diagnostics,  
Vivianna Van Deerlin, MD, PhD, Director, Molecular Pathology Laboratory

Date: February 15, 2024

Re: NEW ASSAY: Apolipoprotein E (*APOE*) genotyping for Alzheimer's disease risk

In February, *APOE* genotyping will be available in the Molecular Pathology Laboratory at the Hospital of the University of Pennsylvania. This assay will determine a patient's *APOE* genotype for the purpose of Alzheimer's disease (AD) risk stratification as well as assess the risk of developing amyloid related imaging abnormalities (ARIA) prior to initiation of anti-amyloid therapeutics, such as lecanemab. This test will replace the current sent out test for Alzheimer's disease risk only. *APOE* genotyping for cardiovascular risk will still be sent out, but will be added in the future.

#### Result Reporting:

The following *APOE* genotypes will be reported: e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, e4/e4.

A full report will be available in PennChart and additionally, the discrete genotype results will be available in the Precision Medicine tab of PennChart.

#### Testing Information:

**Turnaround Time:** 2-10 days

**PennChart Ordering:** APOLIPOPROTEIN E GENOTYPING, ALZHEIMER RISK (PxCode: APOEAR)

#### Acceptable Specimens:

- Peripheral blood collected in an EDTA (lavender) tube
- OraCollect-Dx oral swabs or saliva
- Fresh/Frozen tissue
- Extracted DNA

**Contact Information:** Call the Molecular Pathology Laboratory (215-615-3094) on weekdays during regular business hours. For information on ordering and specimen requirements, kindly consult the [Lab Tests Services Guide](#).